Search ARM

ARM Events

Cell & Gene Therapies State of the Industry Briefing

Back to ARM Events

Cell & Gene Therapies State of the Industry Briefing

Back to ARM Events

Cell & Gene Therapies State of the Industry Briefing

About the Briefing

Join us for the Alliance for Regenerative Medicine’s 10th Annual Cell & Gene Therapies State of the Industry Briefing, a top-level gathering for key stakeholders in the field. This event – which is free and open to the public – will include ARM’s annual yearly update on the sector’s progress, as well as two panels featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in 2020. With an anticipated audience of over 500, this session is the largest cell and gene therapy-focused event taking place during JP Morgan week.

Check back soon for to see who will be speaking at the 2020 program!


View the 2019 Webcast

Couldn’t attend this year’s Cell & Gene Therapies State of the Industry Briefing in-person or looking to have a copy of the slides to reference again? View the full webcast below and download the 2019 Industry Update PPT presentation.

Click to accept cookies and enable this content

To see all three of the video options click on the horizontal bars in the upper left corner.

Download Presentation


2019 Agenda

8:00am – 8:20am | Introduction & Industry Update

Janet Lambert, CEO, Alliance for Regenerative Medicine

8:20am – 9:05am | Cell Therapy Commercialization in Oncology

Joanne Beck, EVP, Global Pharmaceutical Development and Operations, Celgene Corporation
Maria Fardis, President and CEO, Iovance Biotherapeutics
Steven Kelly, President and CEO, CARISMA Therapeutics
Phil Vanek, General Manager, Cell Therapy Growth Strategies, GE Healthcare Life Sciences (chair)
Christopher Vann, Chief Operating Officer, Autolus Therapeutics

9:05am – 9:50am | The Outlook for Gene Therapy in 2019

Dan Faga, Chief Business Officer, Spark Therapeutics
Matthew Kane,
 Co-Founder and CEO, Precision BioSciences
Matthew Patterson,
 Chairman and CEO, Audentes Therapeutics; Chairman, Alliance for Regenerative Medicine (chair)
Arthur Tzianabos,
President and CEO, Homology Medicines
Jeffrey Walsh, Chief Financial and Strategy Officer, bluebird bio

9:50am | Program Close
January 13, 2020

Parc 55 San Francisco, A Hilton Hotel

55 Cyril Magnin St.
San Francisco, CA 94102

Who Attends?

Over 500 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.


Please contact Jeanette Lazusky at